Clinical efficacy of nano-hydroxyapatite combined with one-time root canal therapy in the treatment of pulpitis

Abstract

This study investigates the clinical efficacy of nano-hydroxyapatite (nHA) combined with one-time root canal therapy in the treatment of pulpitis. A total of 92 patients diagnosed with pulpitis and treated at our hospital between September 2021 and November 2022 were selected and randomly designed into a control group filled with calcium hydroxide paste and gutta-percha (n = 46) or an observation group filled with nHA and gutta-percha (n = 46). We compare the cure rate, complication rate, and recurrence rate between the two groups. After treatment, the total effective rate of patients in the observation group was 96.70%, which was significantly higher than 86.00% in the control group. Additionally, the observation group demonstrated lower Visual Analog Scale and Oral Health Impact Profile-14 scores than those of the control group. After treatment, both groups showed reduced serum levels of various inflammatory factors compared to pretreatment values. However, the observation group displayed notably lower levels of serum tumor necrosis factor-α, interleukin-6, and high-sensitivity C-reactive protein compared to their baseline levels. Furthermore, the occlusal force, gingival sulcus bleeding index, and gingival index were significantly lower in the observation group when compared with those in the control group. The incidence of adverse reactions after 6 months of treatment was only 4.30% in the observation group, which was markedly lower than that observed in the control group (18.5%). In summary, we demonstrate the remarkable clinical efficacy of n-HA combined with one-time root canal therapy in the treatment of pulpitis, highlighting its significant potential for clinical application.